Updates in Hepatopancreatobiliary Malignancy 2025: Metastatic Colorectal Cancer and Pancreas Cancer

The management of patients with hepatopancreatobiliary malignancies continues to evolve with the development of novel therapeutics and innovative surgical strategies. These scientific advances have transformed the management of patients with metastatic colorectal cancer and pancreas cancer, leading to improvements in survival and quality of life.

This two-part symposium, offered in-person only, will highlight recent advances in the management of colorectal liver metastases and provide a state-of-the-art update from the David M. Rubenstein Center for Pancreatic Cancer Research.

Part I: Treatment of Colorectal Liver Metastases

The first part of this program will focus on innovations in the management of colorectal cancer metastases to the liver. Sessions will feature expert presentations and interactive discussions on novel therapeutics, emerging biomarkers, and evolving surgical strategies for both resectable and unresectable disease. Dynamic debates will further explore best practices for optimizing patient outcomes.

Part II: Updates in Pancreatic Cancer

The second part of the symposium will provide a state-of-the-art update from the David M. Rubenstein Center for Pancreatic Cancer Research (CPCR) at MSK, highlighting the latest discoveries and therapeutic advances in the management of pancreatic adenocarcinoma.

Networking Reception

A networking reception will follow Thursday’s program, providing an opportunity for faculty and participants to connect, exchange ideas, and foster new collaborations. If you would like to attend the networking reception, please indicate this when completing your registration.

Target Audience

This symposium is intended for medical and surgical oncologists, gastroenterologists, internal medicine specialists, pathologists, geneticists, pharmacists, supportive care staff, advanced practice practitioners, nurses, trainees, and other healthcare professionals. Patients and their families are also welcome to attend complimentary. Please see registration details below for more information.

1. Summarize the evolving role of liver resection for managing hepatic malignancy
2. Discuss the role of regional chemotherapy in the management of metastatic and primary liver cancer
3. Implement recent advances in pancreatic cancer research

This symposium is offered exclusively as an in-person event.

Registration Fees

• Physicians (MDs, PhDs, DOs): $350

• Advanced Practice Providers: $250

• Nurses: $175

• Residents, Fellows, Trainees: $175

• Industry Professionals*: $625

Patients and Caregivers: Please complete our complimentary registration request here.

MSK Employees: Sign in to the MSK CME Portal using your SSO credentials for complimentary registration.

Registration Discounts: Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

Meals and Accommodations: Continental breakfast, lunch, and refreshment breaks will be provided to participants. If you have dietary restrictions or require special accommodations to attend in person, please contact us at [email protected] at least one week prior to the course.

Cancellation Policy: For details on our cancellation terms, please review our Cancellation Policy.

*An “industry professional” is defined as any individual—regardless of profession (e.g., MD, PhD, APP, RN)—who is employed by an ineligible company. View our Registration Policy for Industry Professionals for more information.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 16.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statements

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.50 credits/points in the following certification programs:

• Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification Assessment Recognition Program; and

• Accredited CME and Self-Assessment credits for the American Board of Surgery (ABS) Continuous Certification program.

MOC/CC points will be reported to your board within 45 days of course completion.

ANCC CNE Statement

Memorial Sloan Kettering Cancer Center–Nursing Professional Development / Continuing Education is accredited with distinction as a provider of nursing continuing professional development (NCPD) by the American Nurses Credentialing Center’s Commission on Accreditation.

16.50 contact hours will be awarded to participants who attend the program in its entirety and complete a program evaluation. Partial credit not awarded.

New York State Social Work*

This presentation is approved for a maximum of 16.50 Continuing Education Contact Hours of Live Training. Memorial Sloan Kettering Cancer Center is recognized by the New York State Education Department's State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0228.

*Not all states accept New York State Contact Hours/CEUs. We recommend consulting your state licensing board to confirm whether the credit types offered for this course are accepted.

We look forward to welcoming you to Memorial Sloan Kettering Cancer Center (MSK).

If you’ll be traveling to New York City from out of town, we recommend that you plan your overnight stays as soon as possible. To make the planning a little easier, MSK has negotiated special rates and amenities at select hotels in Manhattan. Click here to view the list of select hotels and additional details on each.

For details on planning your visit to MSK, including travel and parking information, click here. Please note that parking validation is not available for attendees.

If you require any specific accommodations to attend this event in person, please contact [email protected] at least one week in advance.

MSK Symposium Directors

Enid A. Haupt Chair in Surgery
Director, Hepatopancreatobiliary Fellowship Program
Director, Surgical Oncology Fellowship Program
Vice Chair, Education
Attending, Hepatopancreatobiliary Service
Department of Surgery 

William Jarnagin, MD, FACS
Chief, Hepatobiliary Service
Leslie Blumgart Chair in Surgery
Department of Surgery 

Eileen O’Reilly, MD
Winthrop Rockefeller Endowed Chair of Medical Oncology
Chair, Human Research Protection Program and Institutional Review Board
Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers 
Attending, Member, Gastrointestinal Oncology Service
Department of Medicine 

Lily Victoria Saadat, MD
Assistant Attending, Hepatopancreatobiliary Service
Department of Surgery 

MSK Symposium Planning Committee 

Cristy Fitzpatrick, BSN, MA
Advanced Practice Provider 
Hepatopancreatobiliary Service

Mary Helen Larsen, MSN, RN, OCN®
Clinical Trials Nurse

David Hanna, MD
Complex General Surgical Oncology and Hepatopancreatobiliary Clinical Fellow

Judy Schwartz
Patient Planner

Guest Faculty

Tomoaki Kato, MD
Chief, Division of Abdominal Organ Transplant and Hepatobiliary Surgery
Columbia University
New York, NY, USA

Bas Groot Koerkamp, MD, PhD
Professor of Surgery
Erasmus University
Rotterdam, The Netherlands

Michael Lidsky, MD
Associate Professor 
Duke University 
Durham, NC, USA

Hop Tran Cao, MD
Associate Professor 
MD Anderson Cancer Center
Houston, TX, USA

Matthew Weiss, MD
Deputy Physician-in-Chief 
Eli B. & Mollie B. Cohen Family Professor of Surgical Oncology
Northwell Health
New York, NY, USA

MSK Faculty

Vinod Balachandran, MD
Hutham S. Olayan and Robert F. Raucci Chair 
Director, The Olayan Center for Cancer Vaccines
Associate Attending, Hepatopancreatobiliary Service

Xavier Baldwin, MD 
Surgical Oncology Fellow

Fiyinfolu Balogun, MD, PhD
Assistant Attending, Gastrointestinal Oncology Service

Olca Basturk, MD
Attending, Department of Pathology and Laboratory Medicine

Andrea Cercek, MD
Section Head, Colorectal Cancer 
Co-Director for Young Onset Colorectal and Gastrointestinal Cancers
Attending, Gastrointestinal Oncology Service

Sree Bhavani Chalasani, MD
Associate Attending, Gastrointestinal Oncology Service

Louise Catherine Connell, MB BCh BAO, BMedSc
Assistant Attending, Gastrointestinal Oncology Service

Christopher Crane, MD
Attending, Department of Radiation Oncology

Richard Kinh Gian Do, MD, PhD
Director, Hepatobiliary Radiology 
Director, Body MRI
Attending, Body Imaging Service

Mengmeng (Margaret) Du, ScD, MSc
Associate Attending, Department of Epidemiology-Biostatistics

Karuna Ganesh, MD, PhD
Assistant Attending, Gastrointestinal Oncology Service

Marc Hilmi, MD, PhD
Research Fellow

Christine Iacobuzio-Donahue, MD, PhD
David M. Rubenstein Chair
Director, Center for Pancreatic Cancer Research
Attending, Department of Pathology and Laboratory Medicine 

Nancy Kemeny, MD
Emeritus Member, Gastrointestinal Oncology Service

T. Peter Kingham, MD
Director, Global Cancer Research and Training Program
Attending, Hepatopancreatobiliary Service

Jia Li, MD, PhD
Associate Attending, Gastrointestinal Oncology Service

Arnold Markowitz, MD
Attending, Gastroenterology, Hepatology and Nutrition Service

Michael May, MD
Assistant Attending, Gastrointestinal Oncology Service

Robin Mendelsohn, MD
Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers
Associate Attending, Gastroenterology, Hepatology and Nutrition Service

Wungki Park, MD, MS
Assistant Attending, Gastrointestinal Oncology Service

Devika Rao, MD, FACP
Assistant Attending, Gastrointestinal Oncology Service

Marsha Reyngold, MD, PhD
Assistant Attending, Department of Radiation Oncology

Vineet Syan Rolston, MD
Assistant Attending, Gastroenterology, Hepatology and Nutrition Service

Mark Schattner, MD
Chief, Gastroenterology, Hepatology and Nutrition Service

Joshua Schoenfeld, MD, PhD
Instructor, Gastrointestinal Oncology Service

Carlie Sigel, MD
Attending, Department of Pathology and Laboratory Medicine

Anupriya Singhal, MD, PhD
Instructor, Gastrointestinal Oncology Service

Kevin Soares, MD
Hepatopancreatobiliary Fellowship Program Director
Member, David M. Rubenstein Center for Pancreatic Cancer Research
Assistant Attending, Hepatopancreatobiliary Service

Constantinos Sofocleous, MD, PhD
Attending, Interventional Radiology Service

Vlasios Sotirchos, MD
Assistant Attending, Interventional Radiology Service

Zsofia Stadler, MD
Clinical Director, Clinical Genetics Service
Attending, Gastrointestinal Oncology Service

Anna Varghese, MD
Associate Attending, Gastrointestinal Oncology Service

Rona Yaeger, MD
Attending, Gastrointestinal Oncology Service

Hooman Yarmohammadi, MD
Director, IR Research
Attending, Interventional Radiology Service

Kenneth Yu, MD
Associate Attending, Gastrointestinal Oncology Service

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Memorial Sloan Kettering Cancer Center is pleased to announce that the following companies will be exhibiting during this symposium:

Amgen Inc.

Boston Scientific

Revolution Medicines

Taiho Oncology, Inc.